 Biomerica, Inc. BMRA today reported net sales of 1,194,415 for the three months ending August 31, 2019, compared to 1,272,870 for the same period in the previous year. Although revenues in Q1 2020 were slightly lower than the prior year, we expect sales of our specialty diagnostics to begin increasing in Q2, as compared to the same quarterly sales in the previous year, said Zackary Irani, CEO of Biomerica, Inc. We also expect to be near completion of the enrollment of patients for clinical trials for our H. Pylori diagnostic product in fiscal Q2 and plan to submit to the FDA shortly thereafter. Further, during Q2 we plan to announce important progress in the clinical trials for our diagnostic guided therapy, InFoods technology, which we expect to make a significant impact on some of the 45 million Americans who suffer from Irritable Bowel Syndrome IBS. 